YahooSeptember 1, 2026 at 2:44 PM NYLast Month
Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023.
Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
